Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME)
出版年份 2019 全文链接
标题
Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME)
作者
关键词
-
出版物
Journal for ImmunoTherapy of Cancer
Volume 7, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-11-08
DOI
10.1186/s40425-019-0745-3
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- 4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses
- (2018) Ashley V. Menk et al. JOURNAL OF EXPERIMENTAL MEDICINE
- MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma
- (2018) Scott J. Rodig et al. Science Translational Medicine
- Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
- (2018) Peng Jiang et al. NATURE MEDICINE
- Drug response to PD-1/PD-L1 blockade: based on biomarkers
- (2018) Qi Chen et al. OncoTargets and Therapy
- Phase I study of domatinostat (4SC-202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies
- (2018) Bastian von Tresckow et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII
- (2018) Takumi Maruhashi et al. NATURE IMMUNOLOGY
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- (2018) Razvan Cristescu et al. SCIENCE
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8 + T cells in the tumor microenvironment
- (2017) Jason B. Williams et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Targeting myeloid derived suppressor cells with all-trans retinoic acid is highly time-dependent in therapeutic tumor vaccination
- (2017) Annkristin Heine et al. OncoImmunology
- Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma
- (2017) Cathrin Ritter et al. Scientific Reports
- The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition
- (2016) P. S. Hegde et al. CLINICAL CANCER RESEARCH
- HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma
- (2016) Hong Zheng et al. CLINICAL CANCER RESEARCH
- Antigen processing and immune regulation in the response to tumours
- (2016) Emma Reeves et al. IMMUNOLOGY
- PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
- (2016) Paul T. Nghiem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade
- (2016) K. E. Pauken et al. SCIENCE
- Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
- (2016) Douglas B. Johnson et al. Nature Communications
- Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes
- (2016) A. Forero et al. Cancer Immunology Research
- Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
- (2016) Suzanne I.S. Mosely et al. Cancer Immunology Research
- The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat
- (2016) Yusuke Tomita et al. OncoImmunology
- Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
- (2015) Michael S. Rooney et al. CELL
- Overcoming T cell exhaustion in infection and cancer
- (2015) Kristen E. Pauken et al. TRENDS IN IMMUNOLOGY
- HLA Class II Antigen Expression in Colorectal Carcinoma Tumors as a Favorable Prognostic Marker
- (2015) Giuseppe Sconocchia et al. NEOPLASIA
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells
- (2014) K. Kim et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- T-Cell and NK-Cell Infiltration into Solid Tumors: A Key Limiting Factor for Efficacious Cancer Immunotherapy
- (2014) I. Melero et al. Cancer Discovery
- The immune landscape of human tumors
- (2014) Gabriela Bindea et al. OncoImmunology
- Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer
- (2013) Je-In Youn et al. NATURE IMMUNOLOGY
- The Ratios of CD8+ T Cells to CD4+CD25+ FOXP3+ and FOXP3- T Cells Correlate with Poor Clinical Outcome in Human Serous Ovarian Cancer
- (2013) Claudia C. Preston et al. PLoS One
- Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models
- (2012) Li Shen et al. PLoS One
- MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis
- (2011) P. Hemon et al. JOURNAL OF IMMUNOLOGY
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103
- (2010) Amberly Moreno-Bost et al. CYTOTHERAPY
- Epigenetic Enhancement of Antigen Processing and Presentation Promotes Immune Recognition of Tumors
- (2008) A. F. Setiadi et al. CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now